Articles with public access mandates - Norbert KrautLearn more
Available somewhere: 22
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
P Rathert, M Roth, T Neumann, F Muerdter, JS Roe, M Muhar, S Deswal, ...
Nature 525 (7570), 543-547, 2015
Mandates: US National Institutes of Health, Austrian Science Fund, European Commission
BI-3406, a potent and selective SOS1–KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
MH Hofmann, M Gmachl, J Ramharter, F Savarese, D Gerlach, ...
Cancer Discovery 11 (1), 142-157, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
MH Hofmann, D Gerlach, S Misale, M Petronczki, N Kraut
Cancer Discovery 12 (4), 924-937, 2022
Mandates: US National Institutes of Health
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
D Kim, L Herdeis, D Rudolph, Y Zhao, J Böttcher, A Vides, ...
Nature 619 (7968), 160-166, 2023
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Tumor cell‐specific inhibition of MYC function using small molecule inhibitors of the HUWE 1 ubiquitin ligase
S Peter, J Bultinck, K Myant, LA Jaenicke, S Walz, J Müller, M Gmachl, ...
EMBO molecular medicine 6 (12), 1525-1541, 2014
Mandates: Cancer Research UK, Worldwide Cancer Research, UK
Systematic phosphorylation analysis of human mitotic protein complexes
B Hegemann, JRA Hutchins, O Hudecz, M Novatchkova, J Rameseder, ...
Science signaling 4 (198), rs12-rs12, 2011
Mandates: US National Institutes of Health, Austrian Science Fund
Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases
F Hilberg, U Tontsch-Grunt, A Baum, AT Le, RC Doebele, S Lieb, ...
Journal of Pharmacology and Experimental Therapeutics 364 (3), 494-503, 2018
Mandates: US National Institutes of Health
Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts
P van der Lelij, S Lieb, J Jude, G Wutz, CP Santos, K Falkenberg, ...
Elife 6, e26980, 2017
Mandates: US National Institutes of Health, Austrian Science Fund, European Commission
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
S Lieb, S Blaha-Ostermann, E Kamper, J Rippka, C Schwarz, ...
Elife 8, e43333, 2019
Mandates: European Molecular Biology Laboratory, European Commission, Human Frontier …
Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome
K Grosstessner-Hain, B Hegemann, M Novatchkova, J Rameseder, ...
Molecular & cellular proteomics 10 (11), 2011
Mandates: US National Institutes of Health
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
D Gerlach, U Tontsch-Grunt, A Baum, J Popow, D Scharn, MH Hofmann, ...
Oncogene 37 (20), 2687-2701, 2018
Mandates: Fraunhofer-Gesellschaft
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
S Tiede, N Meyer-Schaller, RKR Kalathur, R Ivanek, E Fagiani, ...
Oncogenesis 7 (9), 73, 2018
Mandates: Swiss National Science Foundation, Swiss Cancer Foundation
Selective and potent CDK8/19 inhibitors enhance NK-cell activity and promote tumor surveillance
MH Hofmann, R Mani, H Engelhardt, MA Impagnatiello, S Carotta, ...
Molecular cancer therapeutics 19 (4), 1018-1030, 2020
Mandates: US National Institutes of Health, Government of Spain
Inactivation of Lsd1 triggers senescence in trophoblast stem cells by induction of Sirt4
J Castex, D Willmann, T Kanouni, L Arrigoni, Y Li, M Friedrich, ...
Cell death & disease 8 (2), e2631-e2631, 2017
Mandates: German Research Foundation, European Commission, Federal Ministry of …
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines
K Ehrenhöfer-Wölfer, T Puchner, C Schwarz, J Rippka, ...
Scientific reports 9 (1), 11661, 2019
Mandates: US National Institutes of Health
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
S Schlager, C Salomon, S Olt, C Albrecht, A Ebert, O Bergner, J Wachter, ...
Oncotarget 11 (9), 875, 2020
Mandates: Austrian Science Fund, European Commission
STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers
P van der Lelij, JA Newman, S Lieb, J Jude, V Katis, T Hoffmann, ...
Life Science Alliance 3 (7), 2020
Mandates: Austrian Science Fund, Genome Canada, Wellcome Trust, European Commission …
BI 5700, a selective chemical inhibitor of IκB kinase 2, specifically suppresses epithelial-mesenchymal transition and metastasis in mouse models of tumor progression
MA Huber, HJ Maier, M Alacakaptan, E Wiedemann, J Braunger, ...
Genes & cancer 1 (2), 101-114, 2010
Mandates: German Research Foundation
Antitumor activity of the IGF-1/IGF-2–neutralizing antibody xentuzumab (BI 836845) in combination with enzalutamide in prostate cancer models
U Weyer-Czernilofsky, MH Hofmann, K Friedbichler, R Baumgartinger, ...
Molecular cancer therapeutics 19 (4), 1059-1069, 2020
Mandates: US National Institutes of Health, US Department of Veterans Affairs
RIOK1 kinase activity is required for cell survival irrespective of MTAP status
A Hörmann, B Hopfgartner, T Köcher, M Corcokovic, T Krammer, C Reiser, ...
Oncotarget 9 (47), 28625, 2018
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program